Figures & data
Figure 1 Schema outlining the activation of the human epidermal growth-factor receptor 2 pathway and antibody blockade by trastuzumab and pertuzumab.
![Figure 1 Schema outlining the activation of the human epidermal growth-factor receptor 2 pathway and antibody blockade by trastuzumab and pertuzumab.](/cms/asset/7a93f22a-7a1c-449c-82f1-96057d3f3f95/dpgp_a_37100_f0001_c.jpg)
Table 1 Key randomized clinical trials evaluating pertuzumab therapy for HER2-positive breast cancer
Figure 2 Schema of the NeoSphere clinical trial comparing various neoadjuvant HER2-directed therapies for localized HER2-positive breast cancer.
![Figure 2 Schema of the NeoSphere clinical trial comparing various neoadjuvant HER2-directed therapies for localized HER2-positive breast cancer.](/cms/asset/41863a4f-ad55-44ce-8947-5f7018697925/dpgp_a_37100_f0002_c.jpg)
Figure 3 Schema of the APHINITY clinical trial evaluating efficacy of adjuvant pertuzumab based therapy in localized HER2-positive breast cancer.
Abbreviations: HER, human epidermal growth-factor receptor; IV, intravenous; q3 weeks, every 3 weeks; APHINITY, Adjuvant Pertuzumab and Herceptin in Initial Therapy of Breast Cancer.
![Figure 3 Schema of the APHINITY clinical trial evaluating efficacy of adjuvant pertuzumab based therapy in localized HER2-positive breast cancer.](/cms/asset/8d95a1d9-91ba-4c16-9c2f-5e3163fb30ed/dpgp_a_37100_f0003_c.jpg)
Table 2 Pertuzumab-based chemotherapy regimens as per the US Food and Drug Administration prescribing label (updated September 2013)
Figure 4 Schema of personalized therapy selection based on molecular profiling of breast cancer.
Abbreviations: PI3K, phosphoinositide 3-kinase; HER, human epidermal growth-factor receptor; FGFR, fibroblast growth-factor receptor; HR, hormone receptor.
![Figure 4 Schema of personalized therapy selection based on molecular profiling of breast cancer.](/cms/asset/9a0ead6d-7f25-496c-b108-6f7c2478cd62/dpgp_a_37100_f0004_c.jpg)